<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRIFLUOPERAZINE HYDROCHLORIDE- trifluoperazine hydrochloride tablet, film coated </strong><br>Lake Erie Medical DBA Quality Care Products LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_35718e24-fa79-4e42-b26d-42fc48035ccb"></a><a name="section-1"></a><p></p>
<h1>WARNING</h1>
<p class="First"><span class="Bold">Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></span></p>
<p><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients of between 1.6 to 1.7 times the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were varied, most of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to be either cardiovascular (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) or infectious (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Trifluoperazine hydrochloride is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (see <a href="#i4i_warnings_id_290e8f29-effd-4ef5-a766-84b5985b460c">WARNINGS</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_b42a857c-304c-4b38-94e1-5220dea87256"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each film-coated tablet, for oral administration, contains trifluoperazine hydrochloride, USP equivalent to 1 mg, 2 mg, 5 mg, or 10 mg trifluoperazine.</p>
<p>The structural formula is:</p>
<div class="Figure"><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10b124e8-3167-4b2c-85f1-197b5aa8dabf&amp;name=9e1389f4-c477-458f-b7de-f0f6e3107fe8-01.jpg"></div>
<br><p class="MultiMediaCaption">C<span class="Sub">21</span>H<span class="Sub">24</span>F<span class="Sub">3</span>N<span class="Sub">3</span>S•2HCl               M.W. 480.43</p>
<p class="MultiMediaCaption">C<span class="Sub">21</span>H<span class="Sub">24</span>F<span class="Sub">3</span>N<span class="Sub">3</span>S•2HCl               M.W. 480.43</p>
<p>10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl) phenothiazine dihydrochloride</p>
<p>In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, pregelatinized starch, sodium lauryl sulfate, titanium dioxide, and triacetin. The 5 mg and 10 mg tablets contain the following coloring agents: D&amp;C Red No. 30 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake, and FD&amp;C Yellow No. 6 Aluminum Lake.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_cd4f0ca2-99f5-4a13-9ca2-9ef256d2bdac"></a><a name="section-2"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">For the management of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.</p>
<p>Trifluoperazine hydrochloride is effective for the short-term treatment of generalized non-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>. However, trifluoperazine hydrochloride is not the first drug to be used in therapy for most patients with non-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines).</p>
<p>When used in the treatment of non-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, trifluoperazine hydrochloride tablets should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hydrochloride tablets at higher doses or for longer intervals may cause persistent <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> that may prove irreversible (see <a href="#i4i_warnings_id_290e8f29-effd-4ef5-a766-84b5985b460c">WARNINGS</a>).</p>
<p>The effectiveness of trifluoperazine hydrochloride as a treatment for non-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> was established in a 4-week clinical multicenter study of outpatients with <span class="product-label-link" type="condition" conceptid="434613" conceptname="Generalized anxiety disorder">generalized anxiety disorder</span> (DSM-III). This evidence does not predict that trifluoperazine hydrochloride tablets will be useful in patients with other non-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> conditions in which <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, or signs that mimic <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, are found (i.e., physical illness, organic mental conditions, <span class="product-label-link" type="condition" conceptid="4308866" conceptname="Agitated depression">agitated depression</span>, character pathologies, etc.).</p>
<p>Trifluoperazine hydrochloride has not been shown effective in the management of behavioral complications in patients with <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_c19ec4a5-608c-48c8-a06c-ef57b72e31ed"></a><a name="section-3"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">A known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to phenothiazines, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> or greatly <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressed states</span> due to central nervous system depressants and, in cases of existing <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> and preexisting <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_290e8f29-effd-4ef5-a766-84b5985b460c"></a><a name="section-4"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bfd9693a-4265-4212-8dca-ded64ee0aa7f"></a><a name="section-4.1"></a><p></p>
<h2>Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span></h2>
<p class="First"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Trifluoperazine hydrochloride is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (see <a href="#id_35718e24-fa79-4e42-b26d-42fc48035ccb">BOXED WARNING</a>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7d77a5a3-1f9d-442b-83dc-c59e88c5b358"></a><a name="section-4.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span>, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> is unknown. </p>
<p>Both the risk of developing the syndrome and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. </p>
<p>There is no known treatment for established cases of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying disease process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. </p>
<p>Given these considerations, antipsychotics should be prescribed in a manner that is most likely to minimize the occurrence of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that 1) is known to respond to antipsychotic drugs, and, 2) for whom alternative, equally effective, but potentially less harmful treatments are <span class="Italics">not</span> available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.</p>
<p>If signs and symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> appear in a patient on antipsychotics, drug discontinuation should be considered. However, some patients may require treatment despite the presence of the syndrome.</p>
<p>For further information about the description of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> and its clinical detection, please refer to the sections on <a href="#i4i_precautions_id_3ce35c07-d9c0-4b64-92ae-a6cbfda3dd66">PRECAUTIONS</a> and <a href="#i4i_adverse_effects_id_2b0d7948-28b9-4025-b314-b6aac4b686c5">ADVERSE REACTIONS</a>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_639d1f50-ae0a-40b9-ad9c-3d6f2ba1d259"></a><a name="section-4.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</h2>
<p class="First">A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>).</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span> and primary central nervous system (CNS) pathology. </p>
<p>The management of NMS should include 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.</p>
<p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.</p>
<p>An encephalopathic syndrome (characterized by <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, elevated serum enzymes, BUN and FBS) has occurred in a few patients treated with lithium plus an antipsychotic. In some instances, the syndrome was followed by irreversible <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span>. Because of a possible causal relationship between these events and the concomitant administration of lithium and antipsychotics, patients receiving such combined therapy should be monitored closely for early evidence of neurologic toxicity and treatment discontinued promptly if such signs appear. This encephalopathic syndrome may be similar to or the same as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span> (NMS).</p>
<p>Patients who have demonstrated a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) with a phenothiazine should not be reexposed to any phenothiazine, including trifluoperazine hydrochloride, unless in the judgment of the physician the potential benefits of treatment outweigh the possible hazard. </p>
<p>Trifluoperazine hydrochloride may impair mental and/or physical abilities, especially during the first few days of therapy. Therefore, caution patients about activities requiring alertness (e.g., operating vehicles or machinery). </p>
<p>If agents such as sedatives, narcotics, anesthetics, tranquilizers or alcohol are used either simultaneously or successively with the drug, the possibility of an undesirable additive depressant effect should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8a94d727-3642-4f0a-8263-c42ec3bd1ed8"></a><a name="section-4.4"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">Safety for the use of trifluoperazine hydrochloride during pregnancy has not been established. Therefore, it is not recommended that the drug be given to pregnant patients except when, in the judgment of the physician, it is essential. The potential benefits should clearly outweigh possible hazards. There are reported instances of prolonged <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, extrapyramidal signs, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span> or <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">hyporeflexia</span> in newborn infants whose mothers received phenothiazines. </p>
<p>Reproductive studies in rats given over 600 times the human dose showed an increased incidence of malformations above controls and reduced litter size and weight linked to maternal toxicity. These effects were not observed at half this dosage. No adverse effect on fetal development was observed in rabbits given 700 times the human dose nor in monkeys given 25 times the human dose.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b3779211-abfb-40a2-b4e0-9c79a6f0baac"></a><a name="section-4.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_c24572d6-6e50-4e71-8759-fa5f141b2057"></a><a name="section-4.5.1"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Neonates exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> and <span class="product-label-link" type="condition" conceptid="434750" conceptname="Feeding difficulties and mismanagement">feeding disorder</span> in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.</p>
<p>Trifluoperazine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_6f4813a9-06f7-4488-a44b-2fa3f405dc4e"></a><a name="section-4.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">There is evidence that phenothiazines are excreted in the breast milk of nursing mothers. Because of the potential for serious adverse reactions in nursing infants from trifluoperazine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_3ce35c07-d9c0-4b64-92ae-a6cbfda3dd66"></a><a name="section-5"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_eb382f6b-d2c4-4fe3-bccb-42b23bfbdd72"></a><a name="section-5.1"></a><p></p>
<h2>General</h2>
<p class="First">Given the likelihood that some patients exposed chronically to antipsychotics will develop <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided. </p>
<p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> have been reported in patients receiving the drug. <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> have also been reported-warn patients to report the sudden appearance of <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> or other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. If white blood cell and differential counts indicate cellular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, stop treatment and start antibiotic and other suitable therapy. </p>
<p><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> of the cholestatic type of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> has been reported. If <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment. </p>
<p>One result of therapy may be an increase in mental and physical activity. For example, a few patients with <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> have complained of increased <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> while taking the drug. Therefore, angina patients should be observed carefully and, if an unfavorable response is noted, the drug should be withdrawn. </p>
<p>Because <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has occurred, large doses and parenteral administration should be avoided in patients with impaired cardiovascular systems. To minimize the occurrence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> after injection, keep patient lying down and observe for at least 1/2 hour. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs from parenteral or oral dosing, place patient in head-low position with legs raised. If a vasoconstrictor is required, norepinephrine bitartrate and phenylephrine hydrochloride are suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure. </p>
<p>Since certain phenothiazines have been reported to produce <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>, the drug should be discontinued if ophthalmoscopic examination or visual field studies should demonstrate retinal changes. </p>
<p>An antiemetic action of trifluoperazine hydrochloride may mask the signs and symptoms of toxicity or overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span> and Reye’s syndrome.</p>
<p>With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe central nervous system or vasomotor symptoms, should be kept in mind. </p>
<p>Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately 1/3 of human breast cancers are prolactin-dependent <span class="Italics">in vitro</span>, a factor of potential importance if the prescribing of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.</p>
<p>Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain antipsychotics.</p>
<p>Because phenothiazines may interfere with thermoregulatory mechanisms, use with caution in persons who will be exposed to extreme heat.</p>
<p>As with all drugs which exert an anticholinergic effect, and/or cause <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, trifluoperazine should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. </p>
<p>Phenothiazines may diminish the effect of oral anticoagulants. </p>
<p>Phenothiazines can produce alpha-adrenergic blockade. </p>
<p>Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs. </p>
<p>Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. </p>
<p>Thiazide diuretics may accentuate the <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> that may occur with phenothiazines. </p>
<p>Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of phenytoin and thus precipitate phenytoin toxicity. </p>
<p>Drugs which lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, including phenothiazine derivatives, should not be used with metrizamide. As with other phenothiazine derivatives, trifluoperazine hydrochloride should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours post procedure and should not be used for the control of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurring either prior to myelography or post procedure with metrizamide. </p>
<p>The presence of phenothiazines may produce false-positive <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">phenylketonuria</span> (PKU) test results.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_758768b8-f19a-4a4e-a246-22f0a0764c06"></a><a name="section-5.2"></a><p></p>
<h2>Long-Term Therapy</h2>
<p class="First">To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with trifluoperazine hydrochloride and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_90fc1a46-cc8d-4d7a-8a70-e95ddf5017de"></a><a name="section-5.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></h2>
<p class="First">In clinical trial and post-marketing experience, events of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported temporally related to antipsychotic agents.</p>
<p>Possible risk factors for <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> include preexisting low white blood cell count (WBC) and history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Patients with a preexisting low WBC or a history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue Trifluoperazine Hydrochloride Tablets, USP at the first sign of a decline in WBC in the absence of other causative factors.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should be carefully monitored for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms or signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and treated promptly if such symptoms occur. Patients with severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count &lt; 1000/mm<span class="Sup">3</span>) should discontinue Trifluoperazine Hydrochloride Tablets, USP and have their WBC followed until recovery.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_2b0d7948-28b9-4025-b314-b6aac4b686c5"></a><a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, lactation, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and neuromuscular (extrapyramidal) reactions. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f601df87-4c4c-4b83-aeb4-09c49849b45c"></a><a name="section-6.1"></a><p></p>
<h2>Neuromuscular (Extrapyramidal) Reactions</h2>
<p class="First">These symptoms are seen in a significant number of hospitalized mental patients. They may be characterized by <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">motor restlessness</span>, be of the dystonic type, or they may resemble <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>.</p>
<p>Depending on the severity of symptoms, dosage should be reduced or discontinued. If therapy is reinstituted, it should be at a lower dosage. Should these symptoms occur in children or pregnant patients, the drug should be stopped and not reinstituted. In most cases, barbiturates by suitable route of administration will suffice. (Or, injectable diphenhydramine hydrochloride may be useful.) In more severe cases, the administration of an antiparkinsonism agent, except levodopa, usually produces rapid reversal of symptoms. Suitable supportive measures such as maintaining a clear airway and adequate hydration should be employed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_15fed879-c668-4119-9123-f2c35d6dbe14"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Motor Restlessness</span></h2>
<p class="First">Symptoms may include <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> or <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span> and sometimes <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. These symptoms often disappear spontaneously. At times these symptoms may be similar to the original neurotic or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms. Dosage should not be increased until these side effects have subsided. </p>
<p>If this phase becomes too troublesome, the symptoms can usually be controlled by a reduction of dosage or change of drug. Treatment with antiparkinsonism agents, benzodiazepines or propranolol may be helpful.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7a7cebd7-5d6a-4a0d-9eb6-7ace331a82ba"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c46f54e5-1130-4269-8507-f0f1e9ad39fb"></a><a name="section-6.3.1"></a><p></p>
<h3>Class Effect</h3>
<p class="First">Symptoms of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> is observed in males and younger age groups.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b7c1d8f5-1511-4474-a9c2-3ee5d3742bbf"></a><a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Pseudoparkinsonism</span></h2>
<p class="First">Symptoms may include: mask-like facies; <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span>; <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>; pill-rolling motion; <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span>; and shuffling gait. Reassurance and sedation are important. In most cases these symptoms are readily controlled when an antiparkinsonism agent is administered concomitantly. Antiparkinsonism agents should be used only when required. Generally, therapy of a few weeks to 2 or 3 months will suffice. After this time, patients should be evaluated to determine their need for continued treatment. (Note: Levodopa has not been found effective in <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">pseudoparkinsonism</span>.) Occasionally it is necessary to lower the dosage of trifluoperazine hydrochloride or to discontinue the drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d8461972-5a99-427a-8d19-47b4f2e7bcc5"></a><a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></h2>
<p class="First">As with all antipsychotic agents, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> may appear in some patients on long-term therapy or may appear after drug therapy has been discontinued. The syndrome can also develop, although much less frequently, after relatively brief treatment periods at low doses. This syndrome appears in all age groups. Although its prevalence appears to be highest among elderly patients, especially elderly women, it is impossible to rely upon prevalence estimates to predict at the inception of antipsychotic treatment which patients are likely to develop the syndrome. The symptoms are persistent and in some patients appear to be irreversible. The syndrome is characterized by rhythmical involuntary movements of the tongue, face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). Sometimes these may be accompanied by involuntary movements of extremities. In rare instances, these involuntary movements of the extremities are the only manifestations of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. A variant of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, tardive <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, has also been described. </p>
<p>There is no known effective treatment for <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>; antiparkinsonism agents do not alleviate the symptoms of this syndrome. If clinically feasible, it is suggested that all antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, the syndrome may be masked. </p>
<p>It has been reported that fine vermicular movements of the tongue may be an early sign of the syndrome and if the medication is stopped at that time the syndrome may not develop. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5917e653-93a5-4baf-92c1-0bbaa5b47a4c"></a><a name="section-6.6"></a><p></p>
<h2>Adverse Reactions Reported with Trifluoperazine Hydrochloride or Other Phenothiazine Derivatives</h2>
<p class="First">Adverse effects with different phenothiazines vary in type, frequency, and mechanism of occurrence, i.e., some are dose related, while others involve individual patient sensitivity. Some adverse effects may be more likely to occur, or occur with greater intensity, in patients with special medical problems, e.g., patients with <span class="product-label-link" type="condition" conceptid="443962" conceptname="Mitral valve regurgitation">mitral insufficiency</span> or <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> have experienced severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> following recommended doses of certain phenothiazines.</p>
<p><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with antipsychotic drugs. (See <a href="#i4i_warnings_id_290e8f29-effd-4ef5-a766-84b5985b460c">WARNINGS</a>.)</p>
<p>Not all of the following adverse reactions have been observed with every phenothiazine derivative, but they have been reported with one or more and should be borne in mind when drugs of this class are administered: <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> (<span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonos</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>) some of which have lasted months and even years–particularly in elderly patients with previous <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span>; <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal</span> and <span class="product-label-link" type="condition" conceptid="44801879" conceptname="Petit mal epilepsy">petit mal convulsions</span>, particularly in patients with EEG abnormalities or history of such disorders; altered <span class="product-label-link" type="condition" conceptid="4222478" conceptname="Measurement of protein in cerebrospinal fluid specimen">cerebrospinal fluid proteins</span>; <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>; intensification and prolongation of the action of central nervous system depressants (opiates, analgesics, antihistamines, barbiturates, alcohol), atropine, heat, organophosphorus insecticides; autonomic reactions (dryness of mouth, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">obstipation</span>, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">adynamic ileus</span>, ejaculatory disorders/<span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, atonic colon, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>); reactivation of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> processes, <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonic</span>-like states; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (sometimes fatal); <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>; <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> (<span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>); <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">biliary stasis</span>); endocrine disturbances (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, lactation, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, menstrual irregularities, false-<span class="product-label-link" type="condition" conceptid="4094910" conceptname="Pregnancy test positive">positive pregnancy tests</span>); <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorders</span> (<span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span> up to <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>); other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>); <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>; reversed epinephrine effect; <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>; <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>; increased weight; a <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>-like syndrome; pigmentary <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>; with prolonged administration of substantial doses, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">skin pigmentation</span>, epithelial <span class="product-label-link" type="condition" conceptid="436695" conceptname="Band-shaped keratopathy">keratopathy</span>, and lenticular and <span class="product-label-link" type="condition" conceptid="4080669" conceptname="Keratic precipitates">corneal deposits</span>. </p>
<p>EKG changes-particularly nonspecific, usually reversible Q and T wave distortions-have been observed in some patients receiving phenothiazine antipsychotics. Although phenothiazines cause neither psychic nor physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, sudden discontinuance in long-term psychiatric patients may cause temporary symptoms, e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span>.</p>
<p><span class="Italics">Note:</span> There have been occasional reports of <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> in patients receiving phenothiazines. In some cases, the cause appeared to be <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> or <span class="product-label-link" type="condition" conceptid="4139960" conceptname="Strangulation">asphyxia</span> due to failure of the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_8c4d8c4e-c2b1-4d0f-b5e8-41ed2a52edf2"></a><a name="section-7"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">(See also under <a href="#i4i_adverse_effects_id_2b0d7948-28b9-4025-b314-b6aac4b686c5">ADVERSE REACTIONS</a>.)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_31a1e535-3a6f-4b3f-bc75-d090b46dd135"></a><a name="section-7.1"></a><p></p>
<h2>Symptoms</h2>
<p class="First">Primarily involvement of the extrapyramidal mechanism producing some of the <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span> described above. Symptoms of central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> to the point of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> may also occur. Other possible manifestations include <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, EKG changes and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and autonomic reactions such as <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_47a959f3-797b-4a09-b27f-38de7ce01b9d"></a><a name="section-7.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">It is important to determine other medications taken by the patient since multiple dose therapy is common in overdosage situations. Treatment is essentially symptomatic and supportive. Early gastric lavage is helpful. Keep patient under observation and maintain an open airway, since involvement of the extrapyramidal mechanism may produce <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> and respiratory difficulty in severe overdosage. <span class="Bold">Do not attempt to induce <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> because a <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reaction</span> of the head or neck may develop that could result in <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> of vomitus. </span><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span> may be treated with antiparkinsonism drugs, barbiturates, or diphenhydramine hydrochloride. See prescribing information for these products. Care should be taken to avoid increasing <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. If administration of a stimulant is desirable, amphetamine, dextroamphetamine, or caffeine with sodium benzoate is recommended. Stimulants that may cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> (e.g., picrotoxin or pentylenetetrazol) should be avoided. </p>
<p>If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the standard measures for managing circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> should be initiated. If it is desirable to administer a vasoconstrictor, norepinephrine bitartrate and phenylephrine hydrochloride are most suitable. Other pressor agents, including epinephrine, are not recommended because phenothiazine derivatives may reverse the usual elevating action of these agents and cause a further lowering of blood pressure. </p>
<p>Limited experience indicates that phenothiazines are <span class="Italics">not</span> dialyzable. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_70ec41f1-b181-4a2f-9405-6fe4fdfe84af"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION-ADULTS</h1>
<p class="First">Dosage should be adjusted to the needs of the individual. The lowest effective dosage should always be used. Dosage should be increased more gradually in debilitated or emaciated patients. When maximum response is achieved, dosage may be reduced gradually to a maintenance level. Because of the inherent long action of the drug, patients may be controlled on convenient b.i.d. administration; some patients may be maintained on once a day administration.</p>
<p>When trifluoperazine hydrochloride is administered by intramuscular injection, equivalent oral dosage may be substituted once symptoms have been controlled. </p>
<p>Note: Although there is little likelihood of <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> due to the drug, persons with known sensitivity to phenothiazine drugs should avoid direct contact. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ec8aedcc-4d24-4518-9751-2d9bf0a050d2"></a><a name="section-8.1"></a><p></p>
<h2>Elderly Patients</h2>
<p class="First">In general, dosages in the lower range are sufficient for most elderly patients. Since they appear to be more susceptible to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and neuromuscular reactions, such patients should be observed closely. Dosage should be tailored to the individual, response carefully monitored, and dosage adjusted accordingly. Dosage should be increased more gradually in elderly patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b25bb4a0-f09a-4feb-a354-5ba40d09008a"></a><a name="section-8.2"></a><p></p>
<h2>Non-<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></h2>
<p class="First">Usual dosage is 1 mg or 2 mg twice daily. Do not administer at doses of more than 6 mg per day or for longer than 12 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6caf83b7-9ba9-4485-854e-7b452b7ee211"></a><a name="section-8.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_beb31bb3-d503-4488-b6e9-8939659954b2"></a><a name="section-8.3.1"></a><p></p>
<h3>Oral</h3>
<p class="First">Usual starting dosage is 2 mg to 5 mg b.i.d. (Small or emaciated patients should always be started on the lower dosage.)</p>
<p>Most patients will show optimum response on 15 mg or 20 mg daily, although a few may require 40 mg a day or more. Optimum therapeutic dosage levels should be reached within 2 or 3 weeks.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fe2a44a1-bea3-49f3-b678-4c32d069ef89"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION-<span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">SCHIZOPHRENIA</span> IN CHILDREN</h1>
<p class="First">Dosage should be adjusted to the weight of the child and severity of the symptoms. These dosages are for children, ages 6 to 12, who are hospitalized or under close supervision.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dc33042c-1d14-418c-9ae6-407c6e48b123"></a><a name="section-9.1"></a><p></p>
<h2>Oral</h2>
<p class="First">The starting dosage is 1 mg administered once a day or b.i.d. Dosage may be increased gradually until symptoms are controlled or until side effects become troublesome. </p>
<p>While it is usually not necessary to exceed dosages of 15 mg daily, some older children with severe symptoms may require higher dosages.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_246fc0ec-a7ad-4e0a-9c66-1530b02ca250"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Trifluoperazine Hydrochloride Tablets, USP are available containing trifluoperazine hydrochloride, USP equivalent to 1 mg, 2 mg, 5 mg or 10 mg of trifluoperazine.</p>
<p>The 1 mg tablets are white film-coated, round, unscored tablets debossed with <span class="Bold">T3</span> on one side of the tablet and <span class="Bold">M </span>on the other side. They are available as follows:</p>
<p>NDC 0378-2401-01<br>bottles of 100 tablets</p>
<p>The 2 mg tablets are white film-coated, round, unscored tablets debossed with <span class="Bold">T4</span> on one side of the tablet and <span class="Bold">M </span>on the other side. They are available as follows:</p>
<p>NDC 0378-2402-01<br>bottles of 100 tablets</p>
<p>For psychiatric patients who are hospitalized under close supervision.</p>
<p>The 5 mg tablets are lavender film-coated, round, unscored tablets debossed with <span class="Bold">T5</span> on one side of the tablet and <span class="Bold">M </span>on the other side. They are available as follows:</p>
<p>NDC 0378-2405-01<br>bottles of 100 tablets</p>
<p>The 10 mg tablets are lavender film-coated, round, unscored tablets debossed with <span class="Bold">T6</span> on one side of the tablet and <span class="Bold">M</span> on the other side. They are available as follows:</p>
<p>NDC 0378-2410-01<br>bottles of 100 tablets</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505</p>
<p>REVISED SEPTEMBER 2010<br>TFPZ:R9</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Le471db27-2c61-4c40-a646-098c95907e60"></a><a name="section-11"></a><p></p>
<h1>Image of Label</h1>
<p class="First"><img alt="Image of Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10b124e8-3167-4b2c-85f1-197b5aa8dabf&amp;name=TrifluoperazineHCL1mgMylan.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRIFLUOPERAZINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">trifluoperazine hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:35356-823(NDC:0378-2401)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRIFLUOPERAZINE HYDROCHLORIDE</strong> (TRIFLUOPERAZINE) </td>
<td class="formItem">TRIFLUOPERAZINE</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">T3;M</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:35356-823-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:35356-823-60</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:35356-823-90</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040209</td>
<td class="formItem">08/22/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Lake Erie Medical DBA Quality Care Products LLC
							(831276758)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lake Erie Medical DBA Quality Care Products LLC</td>
<td class="formItem"></td>
<td class="formItem">831276758</td>
<td class="formItem">repack(35356-823)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>55a9cb2a-2c00-4e4a-adce-d48cc6ce1b23</div>
<div>Set id: 10b124e8-3167-4b2c-85f1-197b5aa8dabf</div>
<div>Version: 1</div>
<div>Effective Time: 20130610</div>
</div>
</div> <div class="DistributorName">Lake Erie Medical DBA Quality Care Products LLC</div></p>
</body></html>
